Please join Gain Therapeutics for a virtual key opinion leader (KOL) event discussing the role of GCase substrates in Parkinson’s disease and how changes in these substrates inform target engagement, pathway modulation, and disease progression.

The event will also review biomarker results from the Phase 1b clinical study of GT-02287, demonstrating disease modifying potential in Parkinson’s disease patients with or without a GBA1 mutation.

Participating KOLs:

• Roy Alcalay, M.D., M.Sc. – Chief of Movement Disorders Division, Tel Aviv Sourasky Medical Center, Professor of Neurology, Tel Aviv University, Associate Professor of Clinical Neurology, Columbia University
• Peter Lansbury, Ph.D. – Professor of Neurology, Harvard

A live question and answer session will follow the formal presentations.